Patents Assigned to United Therapeutics Corporation
  • METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20240139207
    Abstract: The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertension followed by an orally administered form of a therapeutic agent for treating pulmonary hypertension, wherein the amount of non-oral therapeutic agent is sufficient to allow for an increased amount of the orally administered therapeutic agent to thereafter be administered compared to a subject who is not previously treated with the non-oral therapeutic agent.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 2, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Meredith Broderick, Andrew Nelsen
  • TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS
    Publication number: 20240131078
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • STABLE TREPROSTINIL PRODRUGS
    Publication number: 20240130989
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: November 27, 2023
    Publication date: April 25, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
    Publication number: 20240100003
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: December 11, 2023
    Publication date: March 28, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • PRODRUGS OF TREPROSTINIL
    Publication number: 20240058287
    Abstract: Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 22, 2024
    Applicants: United Therapeutics Corporation, MannKind Corporation
    Inventors: Hitesh BATRA, Liang GUO, Patrick POISSON, Sri Harsha TUMMALA, Elizabeth Ann HARRIS
  • TREPROSTINIL PRODRUGS
    Publication number: 20240051979
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: March 10, 2023
    Publication date: February 15, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
    Patent number: 11839631
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: December 12, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
    Patent number: 11839596
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: December 12, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Treatment for interstitial lung disease
    Patent number: 11826327
    Abstract: Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: November 28, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Leigh Peterson, Peter Smith, Chunqin Deng
  • Stable treprostinil prodrugs
    Patent number: 11826328
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: November 28, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN REMODULIN®
    Publication number: 20230338313
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh BATRA, Sudersan M. TULADHAR, Raju PENMASTA, David A. WALSH
  • Prodrugs of treprosiinil
    Patent number: 11793780
    Abstract: Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: October 24, 2023
    Assignees: United Therapeutics Corporation, Mann Kind Corporation
    Inventors: Hitesh Batra, Liang Guo, Patrick Poisson, Sri Harsha Tummala, Elizabeth Ann Harris
  • TREPROSTINIL ILOPROST COMBINATION THERAPY
    Publication number: 20230263807
    Abstract: The disclosure relates to treatment of a disease, such as pulmonary hypertension, by inhalation with a combination of iloprost and treprostinil.
    Type: Application
    Filed: February 7, 2023
    Publication date: August 24, 2023
    Applicant: United Therapeutics Corporation
    Inventors: Patrick Poisson, Ravi Patel, Robert Stewart Gurley, Elizabeth Anne French
  • Treatment for interstitial lung disease
    Patent number: 11730710
    Abstract: Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: August 22, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Leigh Peterson, Peter Smith, Chunqin Deng
  • TREPROSTINIL PRODRUGS
    Publication number: 20230255922
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: April 28, 2023
    Publication date: August 17, 2023
    Applicant: United Therapeutics Corporation
    Inventors: Ken PHARES, Hitesh BATRA, Liang GUO, Adam Marc SILVERSTEIN
  • Process to prepare treprostinil, the active ingredient in Remodulin®
    Patent number: 11723887
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: August 15, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Enhanced solubility drug-containing formulations
    Patent number: 11672863
    Abstract: This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: June 13, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Michael Laird Hurrey, Drazen Ostovic, Peter Noymer
  • Treprostinil prodrugs
    Patent number: 11672775
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: June 13, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, Hitesh Batra, Liang Guo, Adam Marc Silverstein
  • METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER
    Publication number: 20230174947
    Abstract: Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.
    Type: Application
    Filed: December 7, 2022
    Publication date: June 8, 2023
    Applicant: United Therapeutics Corporation
    Inventors: Bryan Fioret, Thomas Petersen, Ryan Bonvillain, David Graham, Peter Vu, Lotte van den Goor
  • Treatment of pulmonary arterial hypertension with mesenchymal stem cells
    Patent number: 11666602
    Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 6, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade